Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Diseases AND Chronic Kidney Disease AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: Cardiovascular Diseases AND Chronic Kidney Disease AND Placebo. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2021-005855-35 Sponsor Protocol Number: U1111-1270-0943 Start Date*: 2023-01-10
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascu...
    Medical condition: Atherosclerotic cardiovascular disease and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002428-10 Sponsor Protocol Number: KTxSGLT2i-22 Start Date*: 2023-03-06
    Sponsor Name:Oslo Univeristy Hospital - Rikshospitalet
    Full Title: CAN DAPAGLIFLOZIN PRESERVE STRUCTURE AND FUNCTION IN TRANSPLANTED KIDNEYS?
    Medical condition: Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on graft survival by repeated eGFR measurements, measured GFR, kidney graft biopsies to evaluate inflammation, fibrosis and va...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003025-10 Sponsor Protocol Number: VIVID Start Date*: 2011-11-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease.
    Medical condition: Left ventricular hypertrophy, type 2 diabetes, chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10007541 - Cardiac disorders 10047295 Ventricular hypertrophy PT
    20.0 100000004861 10012612 Diabetes mellitus non insulin-dep LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000770-19 Sponsor Protocol Number: D5740C00001 Start Date*: 2015-01-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on D...
    Medical condition: Anemia in chronic kidney disease patients without dialysis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-003951-39 Sponsor Protocol Number: GS-US-223-1017 Start Date*: 2019-12-09
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Di...
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005092-33 Sponsor Protocol Number: M10-221 Start Date*: 2008-06-10
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5
    Medical condition: Stage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who have left ventricular hypertrophy (LVH).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Prematurely Ended) CZ (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003141-42 Sponsor Protocol Number: EX9924-4473 Start Date*: 2019-07-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Ongoing) CZ (Completed) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005065-40 Sponsor Protocol Number: TA-8995-302 Start Date*: 2022-05-13
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participant...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH) atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005032-42 Sponsor Protocol Number: 17-162 Start Date*: 2020-04-20
    Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty
    Full Title: Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease
    Medical condition: Diabetes Type 2 with existing cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003896-24 Sponsor Protocol Number: D169AC00001 Start Date*: 2017-01-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
    Medical condition: Chronic kidney disease (CKD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Completed) DE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005092-39 Sponsor Protocol Number: TA-8995-304 Start Date*: 2022-08-25
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular...
    Medical condition: atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001303-36 Sponsor Protocol Number: TRCA-303 Start Date*: 2018-11-07
    Sponsor Name:Tricida Inc.
    Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) SK (Completed) CZ (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) NL (Prematurely Ended) PL (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003232-80 Sponsor Protocol Number: 2017-71 Start Date*: 2019-03-04
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine : A Randomized, Double-blind, Placebo-controlled, Cross-over Trial
    Medical condition: Chronic Kidney Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000301-45 Sponsor Protocol Number: BAY94-8862/14563 Start Date*: 2011-05-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, multi-center study to assess safety and tolerability of different oral doses of BAY 94-8862 in subjects with stable chronic heart failure with left ventricular systolic...
    Medical condition: Stable chronic heart failure subjects with left ventricular systolic dysfunction and mild (Part A) or moderate (Part B) chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) DK (Completed) BE (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022630-92 Sponsor Protocol Number: AP214-CS007 Start Date*: 2010-11-05
    Sponsor Name:Action Pharma A/S
    Full Title: An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Su...
    Medical condition: Action Pharma is developing AP214 Acetate for the prevention of postsurgical kidney injury after cardiac surgery. Trial population is patients with increased risk for development of Kidney Inju...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10022117 - Injury, poisoning and procedural complications 10056675 Postoperative renal failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021922-36 Sponsor Protocol Number: 2010-352-UREMINC Start Date*: 2011-05-23
    Sponsor Name:Department of Nephrology, Rigshospitalet, University of Copenhagen
    Full Title: Safety and effect of liraglutide in patients with type 2 diabetes and severe renal insufficiency.
    Medical condition: 1) Patients with type 2 diabetes (T2D) and no or severely reduced kidney function, depending on chronic dialysis treatment. 2) Patients with T2D and normal kidney function.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10041244 - Social circumstances 10012347 Dependence on renal dialysis LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022297-14 Sponsor Protocol Number: 402-C-0903 Start Date*: 2011-10-27
    Sponsor Name:Reata Pharmaceuticals, Inc
    Full Title: Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurence of Renal Events (BEACON)
    Medical condition: Chronic Kidney Disease Stage 4
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001911-96 Sponsor Protocol Number: D9488C00001 Start Date*: 2021-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants wit...
    Medical condition: Chronic kidney disease (CKD) with hyperkalaemia or at risk of hyperkalaemia
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001668-13 Sponsor Protocol Number: GE-012-106 Start Date*: 2017-10-25
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque™ Injection 320 mgI/mL) on Renal Function in ...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000070575 10076410 Chronic kidney disease stage 3 LLT
    20.0 100000070575 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) BE (Prematurely Ended) HU (Completed) PL (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000656-26 Sponsor Protocol Number: BAY1142524/18933 Start Date*: 2017-11-29
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, multicenter study to assess the efficacy and safety of a 6 month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo ...
    Medical condition: type II diabetic mellitus (T2DM) patients with a clinical diagnosis of diabetic kidney disease (CKD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Sep 24 23:10:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA